एपीए उद्धरण

Ricciuti, B., Lamberti, G., Roila, F., & Metro, G. (2019). Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option. Transl Lung Cancer Res.

शिकागो स्टाइल उद्धरण

Ricciuti, Biagio, Giuseppe Lamberti, Fausto Roila, और Giulio Metro. "Brigatinib for Anaplastic Lymphoma Kinase-tyrosine Kinase Inhibitor Naïve Anaplastic Lymphoma Kinase-positive Advanced Non-small Cell Lung Cancer: An Effective but Still Broken Option." Transl Lung Cancer Res 2019.

एमएलए उद्धरण

Ricciuti, Biagio, Giuseppe Lamberti, Fausto Roila, और Giulio Metro. "Brigatinib for Anaplastic Lymphoma Kinase-tyrosine Kinase Inhibitor Naïve Anaplastic Lymphoma Kinase-positive Advanced Non-small Cell Lung Cancer: An Effective but Still Broken Option." Transl Lung Cancer Res 2019.

चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.